https://fhucare.com/our-publications/oncogenetic-landscape-of-lymphomagenesis-in-coeliac-disease/ 2025-12-21T23:00:10+00:00 https://fhucare.com/our-publications/impact-of-an-education-programme-on-ibd-patients-skills-results-of-a-randomised-controlled-multicentre-study-ecipe/ 2025-12-21T23:00:11+00:00 https://fhucare.com/our-publications/notch-inhibitors-induce-diarrhea-hypercrinia-and-secretory-cell-metaplasia-in-the-human-colon/ 2025-12-21T23:00:12+00:00 https://fhucare.com/our-publications/practical-management-of-patients-on-anti-tnf-therapy-practical-guidelines-drawn-up-by-the-club-rhumatismes-et-inflammation-cri/ 2025-12-21T23:00:13+00:00 https://fhucare.com/our-publications/practical-management-of-patients-on-anti-il17-therapy-practical-guidelines-drawn-up-by-the-club-rhumatismes-et-inflammation-cri/ 2025-12-21T23:00:14+00:00 https://fhucare.com/our-publications/risk-of-severe-covid-19-in-patients-treated-with-ibd-medications-a-french-nationwide-study/ 2025-12-21T23:00:15+00:00 https://fhucare.com/our-publications/practical-management-of-patients-on-anti-il6r-therapy-practical-guidelines-drawn-up-by-the-club-rhumatismes-et-inflammation-cri/ 2025-12-21T23:00:16+00:00 https://fhucare.com/our-publications/current-and-future-therapies-for-primary-sjogren-syndrome/ 2025-12-21T23:00:17+00:00 https://fhucare.com/our-publications/inflammation-targeted-therapies-and-cancer/ 2025-12-21T23:00:18+00:00 https://fhucare.com/our-publications/comparative-study-of-pregnancy-outcomes-in-women-with-inflammatory-bowel-disease-treated-with-thiopurines-and-or-anti-tnf-a-french-nationwide-study-2010-2018/ 2025-12-21T23:00:19+00:00 https://fhucare.com/our-publications/tofacitinib-as-salvage-therapy-for-55-patients-hospitalised-with-refractory-severe-ulcerative-colitis-a-getaid-cohort/ 2025-12-21T23:00:20+00:00 https://fhucare.com/our-publications/blockage-of-bacterial-fimh-prevents-mucosal-inflammation-associated-with-crohns-disease/ 2025-12-21T23:00:21+00:00 https://fhucare.com/our-publications/long-term-exposure-to-monoclonal-anti-tnf-is-associated-with-an-increased-risk-of-lymphoma-in-baff-transgenic-mice/ 2025-12-21T23:00:22+00:00 https://fhucare.com/our-publications/chronic-pouchitis-and-crohns-disease-of-the-pouch-after-ileal-pouch-anal-anastomosis-incidence-and-risk-factors/ 2025-12-21T23:00:23+00:00 https://fhucare.com/our-publications/monitoring-established-crohns-disease-with-pan-intestinal-video-capsule-endoscopy-in-europe-clinician-consultation-using-the-nominal-group-technique/ 2025-12-21T23:00:24+00:00 https://fhucare.com/our-publications/lymphoma-complicating-rheumatoid-arthritis-results-from-a-french-case-control-study/ 2025-12-21T23:00:25+00:00 https://fhucare.com/our-publications/response-to-covid-19-mrna-vaccination-in-multiple-myeloma-is-conserved-but-impaired-compared-to-controls/ 2025-12-21T23:00:26+00:00 https://fhucare.com/our-publications/local-treatment-of-pancreatic-cancer-metastases-a-multicenter-french-study-of-the-ageo-group/ 2025-12-21T23:00:27+00:00 https://fhucare.com/our-publications/tumor-necrosis-factor-inhibitors-and-the-risk-of-cancer-among-older-americans-with-rheumatoid-arthritis/ 2025-12-21T23:00:28+00:00 https://fhucare.com/our-publications/hypophosphatemia-following-the-administration-of-intravenous-iron-formulations-a-case-report-and-literature-review/ 2025-12-21T23:00:29+00:00 https://fhucare.com/our-publications/recommendations-for-risk-management-and-better-living-with-epilepsy-phenomenological-study-of-the-experience-of-patients-relatives-and-bereaved-families/ 2025-12-21T23:00:30+00:00 https://fhucare.com/our-publications/articular-manifestations-in-patients-with-inflammatory-bowel-diseases-treated-with-anti-tnf/ 2025-12-21T23:00:31+00:00 https://fhucare.com/our-publications/editorial-subcutaneous-ct-p13-in-crohns-disease-and-ulcerative-colitis-small-change-big-consequences/ 2025-12-21T23:00:32+00:00 https://fhucare.com/our-publications/anti-programmed-death-ligand-1-immunotherapies-in-cancer-patients-with-pre-existing-systemic-sclerosis-a-postmarketed-phase-iv-safety-assessment-study/ 2025-12-21T23:00:33+00:00 https://fhucare.com/our-publications/rheumatic-disorders-associated-with-immune-checkpoint-inhibitors-what-about-myositis-an-analysis-of-the-whos-adverse-drug-reactions-database/ 2025-12-21T23:00:34+00:00 https://fhucare.com/our-publications/using-autoantibodies-to-diagnose-systemic-autoimmune-diseases-triggered-by-immune-checkpoint-inhibitors-a-clinical-perspective/ 2025-12-21T23:00:35+00:00 https://fhucare.com/our-publications/systematic-review-with-meta-analysis-the-effectiveness-of-either-ustekinumab-or-vedolizumab-in-patients-with-crohns-disease-refractory-to-anti-tumour-necrosis-factor/ 2025-12-21T23:00:36+00:00 https://fhucare.com/our-publications/vedolizumab-clinical-decision-support-tool-predicts-efficacy-of-vedolizumab-but-not-ustekinumab-in-refractory-crohns-disease/ 2025-12-21T23:00:37+00:00 https://fhucare.com/our-publications/etrolizumab-as-induction-and-maintenance-therapy-for-ulcerative-colitis-in-patients-previously-treated-with-tumour-necrosis-factor-inhibitors-hickory-a-phase-3-randomised-controlled-trial/ 2025-12-21T23:00:38+00:00 https://fhucare.com/our-publications/etrolizumab-versus-infliximab-for-the-treatment-of-moderately-to-severely-active-ulcerative-colitis-gardenia-a-randomised-double-blind-double-dummy-phase-3-study/ 2025-12-21T23:00:39+00:00 https://fhucare.com/our-publications/features-of-polymyalgia-rheumatica-like-syndrome-after-immune-checkpoint-inhibitor-therapy/ 2025-12-21T23:00:40+00:00 https://fhucare.com/our-publications/sarcoid-like-granulomatosis-associated-with-immune-checkpoint-inhibitors-in-melanoma/ 2025-12-21T23:00:41+00:00 https://fhucare.com/our-publications/toxicity-of-cancer-immunotherapies-traps-to-not-miss-the-role-of-the-internist/ 2025-12-21T23:00:42+00:00 https://fhucare.com/our-publications/meat-intake-is-associated-with-a-higher-risk-of-ulcerative-colitis-in-a-large-european-prospective-cohort-studyo/ 2025-12-21T23:00:43+00:00 https://fhucare.com/our-publications/ocular-inflammation-induced-by-immune-checkpoint-inhibitors/ 2025-12-21T23:00:44+00:00 https://fhucare.com/our-publications/prevalence-and-outcome-of-steroid-resistant-refractory-pneumonitis-induced-by-immune-checkpoint-inhibitors/ 2025-12-21T23:00:45+00:00 https://fhucare.com/our-publications/obesity-is-associated-with-increased-risk-of-crohns-disease-but-not-ulcerative-colitis-a-pooled-analysis-of-five-prospective-cohort-studies/ 2025-12-21T23:00:46+00:00 https://fhucare.com/our-publications/improving-dexamethasone-drug-loading-and-efficacy-in-treating-arthritis-through-a-lipophilic-prodrug-entrapped-into-plga-peg-nanoparticles/ 2025-12-21T23:00:47+00:00 https://fhucare.com/our-publications/targeted-nanotherapy-with-everolimus-reduces-inflammation-and-fibrosis-in-scleroderma-related-interstitial-lung-disease-developed-by-psgl-1-deficient-mice/ 2025-12-21T23:00:48+00:00 https://fhucare.com/our-publications/features-of-non-hodgkins-lymphoma-diagnosed-in-minor-salivary-gland-biopsies-from-primary-sjogrens-syndrome-patients/ 2025-12-21T23:00:49+00:00 https://fhucare.com/our-publications/rituximab-impairs-b-cell-response-but-not-t-cell-response-to-covid-19-vaccine-in-autoimmune-diseases/ 2025-12-21T23:00:50+00:00 https://fhucare.com/our-publications/very-low-rate-of-humoral-response-after-a-third-covid-19-vaccine-dose-in-patients-with-autoimmune-diseases-treated-with-rituximab-and-non-responders-to-two-doses/ 2025-12-21T23:00:51+00:00 https://fhucare.com/our-publications/serious-infections-in-children-born-to-mothers-with-inflammatory-bowel-disease-with-in-utero-exposure-to-thiopurines-and-anti-tumor-necrosis-factor/ 2025-12-21T23:00:52+00:00 https://fhucare.com/our-publications/risk-of-malignancy-in-rheumatoid-arthritis-patients-initiating-biologics-an-historical-propensity-score-matched-cohort-study-within-the-french-nationwide-healthcare-database/ 2025-12-21T23:00:53+00:00 https://fhucare.com/our-publications/health-related-quality-of-life-in-patients-treated-with-pembrolizumab-for-microsatellite-instability-high-mismatch-repair-deficient-advanced-solid-tumours-results-from-the-keynote-158-study/ 2025-12-21T23:00:54+00:00 https://fhucare.com/our-publications/bariatric-surgery-in-patients-with-inflammatory-bowel-disease-a-case-control-study-from-the-getaid/ 2025-12-21T23:00:55+00:00 https://fhucare.com/our-publications/machine-learning-predicts-response-to-tnf-inhibitors-in-rheumatoid-arthritis-results-on-the-espoir-and-abirisk-cohorts/ 2025-12-21T23:00:56+00:00 https://fhucare.com/our-publications/efficacy-and-safety-of-infliximab-retreatment-in-crohns-disease-a-multicentre-prospective-observational-cohort-regain-study-from-the-getaid/ 2025-12-21T23:00:57+00:00 https://fhucare.com/our-publications/immune-related-adverse-events-of-cancer-immunotherapies-targeting-kinases/ 2025-12-21T23:00:58+00:00 https://fhucare.com/our-publications/lack-of-association-between-the-tnfaip3-rs2230926-variant-and-rheumatoid-arthritis-associated-lymphoma/ 2025-12-21T23:00:59+00:00 https://fhucare.com/our-publications/use-of-a-bdmard-or-tsdmard-for-the-management-of-inflammatory-arthritis-under-checkpoint-inhibitors-an-observational-study/ 2025-12-21T23:01:00+00:00 https://fhucare.com/our-publications/benefits-and-risks-associated-with-continuation-of-anti-tumor-necrosis-factor-after-24-weeks-of-pregnancy-in-women-with-inflammatory-bowel-disease-a-nationwide-emulation-trial/ 2025-12-21T23:01:01+00:00 https://fhucare.com/our-publications/circulating-l-arginine-predicts-the-survival-of-cancer-patients-treated-with-immune-checkpoint-inhibitors/ 2025-12-21T23:01:02+00:00 https://fhucare.com/our-publications/immune-related-arthritis-following-pelvic-radiation-therapy-in-a-patient-with-lung-cancer-receiving-long-term-immune-checkpoint-blocker-treatment-case-report/ 2025-12-21T23:01:03+00:00 https://fhucare.com/our-publications/cdkn1a-is-a-target-for-phagocytosis-mediated-cellular-immunotherapy-in-acute-leukemia/ 2025-12-21T23:01:04+00:00 https://fhucare.com/our-publications/tolerance-and-efficacy-of-targeted-therapies-prescribed-for-off-label-indications-in-refractory-systemic-autoimmune-diseases-data-of-the-first-100-patients-enrolled-in-the-tata-registry-targeted-the/ 2025-12-21T23:01:05+00:00 https://fhucare.com/our-publications/analysis-of-the-association-between-prospectively-collected-immune-related-adverse-events-and-survival-in-patients-with-solid-tumor-treated-with-immune-checkpoint-blockers-taking-into-account-immorta/ 2025-12-21T23:01:06+00:00 https://fhucare.com/our-publications/comparative-real-world-effectiveness-of-vedolizumab-and-ustekinumab-for-patients-with-ulcerative-colitis-a-getaid-multicentre-cohort-study/ 2025-12-21T23:01:07+00:00 https://fhucare.com/our-publications/interplay-between-mucus-mobility-and-alveolar-macrophage-targeting-of-surface-modified-liposomes/ 2025-12-21T23:01:08+00:00 https://fhucare.com/our-publications/management-of-toxicities-from-immunotherapy-esmo-clinical-practice-guideline-for-diagnosis-treatment-and-follow-up/ 2025-12-21T23:01:09+00:00 https://fhucare.com/our-publications/lifestyle-factors-for-the-prevention-of-inflammatory-bowel-disease/ 2025-12-21T23:01:10+00:00 https://fhucare.com/our-publications/immunotherapy-advances-in-cancers-with-mismatch-repair-or-proofreading-deficiencies/ 2025-12-21T23:01:11+00:00 https://fhucare.com/our-publications/characterization-and-outcomes-of-414-patients-with-primary-ss-who-developed-haematological-malignancies/ 2025-12-21T23:01:12+00:00 https://fhucare.com/our-publications/janus-kinase-inhibitors-alter-nk-cell-phenotypes-and-inhibit-their-antitumour-capacity/ 2025-12-21T23:01:13+00:00 https://fhucare.com/our-publications/using-genetics-to-predict-toxicity-of-cancer-immunotherapy/ 2025-12-21T23:01:14+00:00 https://fhucare.com/our-publications/editorial-ustekinumab-during-pregnancy-reassuring-but-still-not-enough/ 2025-12-21T23:01:15+00:00 https://fhucare.com/our-publications/efficacy-and-safety-of-combination-targeted-therapies-in-immune-mediated-inflammatory-disease-the-combio-study/ 2025-12-21T23:01:16+00:00 https://fhucare.com/our-publications/immune-related-generalised-oedema-a-new-category-of-adverse-events-with-immune-checkpoint-inhibitors/ 2025-12-21T23:01:17+00:00 https://fhucare.com/our-publications/protective-effect-of-obesity-on-survival-in-cancers-treated-with-immunotherapy-vanishes-when-controlling-for-type-of-cancer-weight-loss-and-reduced-skeletal-muscle/ 2025-12-21T23:01:18+00:00 https://fhucare.com/our-publications/progressive-multifocal-leukoencephalopathy-treated-by-immune-checkpoint-inhibitors/ 2025-12-21T23:01:19+00:00 https://fhucare.com/our-publications/amphiphilic-phosphorus-dendrons-associated-with-anti-inflammatory-sirna-reduce-symptoms-in-murine-collagen-induced-arthritis/ 2025-12-21T23:01:20+00:00 https://fhucare.com/our-publications/cancer-screening-in-chronic-inflammatory-rheumatic-diseases/ 2025-12-21T23:01:21+00:00 https://fhucare.com/our-publications/chemotherapy-in-solitary-bone-plasmacytoma-to-prevent-evolution-to-multiple-myeloma/ 2025-12-21T23:01:22+00:00 https://fhucare.com/our-publications/severe-colitis-in-patients-with-melanoma-treated-with-braf-mek-inhibitors/ 2025-12-21T23:01:23+00:00 https://fhucare.com/our-publications/an-overview-of-immune-checkpoint-inhibitors-toxicities/ 2025-12-21T23:01:24+00:00 https://fhucare.com/our-publications/editorial-in-search-of-environmental-risk-factors-of-crohns-disease-and-ulcerative-colitis-with-mendelian-randomisation/ 2025-12-21T23:01:25+00:00 https://fhucare.com/our-publications/prognosis-of-immune-checkpoint-inhibitors-induced-myocarditis-a-case-series/ 2025-12-21T23:01:26+00:00 https://fhucare.com/our-publications/role-of-c-reactive-protein-in-predicting-the-severity-and-response-of-immune-mediated-diarrhea-and-colitis-in-patients-with-cancer/ 2025-12-21T23:01:27+00:00 https://fhucare.com/our-publications/food-processing-and-risk-of-crohns-disease-and-ulcerative-colitis-a-european-prospective-cohort-study/ 2025-12-21T23:01:28+00:00 https://fhucare.com/our-publications/a-microbiota-modulated-checkpoint-directs-immunosuppressive-intestinal-t-cells-into-cancers/ 2025-12-21T23:01:29+00:00 https://fhucare.com/our-publications/machine-learning-identifies-a-profile-of-inadequate-responder-to-methotrexate-in-rheumatoid-arthritis/ 2025-12-21T23:01:30+00:00 https://fhucare.com/our-publications/response-to-biologic-drugs-in-patients-with-rheumatoid-arthritis-and-antidrug-antibodies/ 2025-12-21T23:01:31+00:00 https://fhucare.com/our-publications/post-transcriptional-checkpoints-in-autoimmunity/ 2025-12-21T23:01:32+00:00 https://fhucare.com/our-publications/liposomal-antagomir-155-5p-restores-anti-inflammatory-macrophages-and-improves-arthritis-in-pre-clinical-models-of-rheumatoid-arthritis/ 2025-12-21T23:01:33+00:00 https://fhucare.com/our-publications/wallflex-and-evolution-duodenal-stents-have-similar-efficacy-but-different-safety-for-malignant-gastric-outlet-obstruction/ 2025-12-21T23:01:34+00:00 https://fhucare.com/our-publications/efficacy-of-daratumumab-in-refractory-primary-sjogren-disease/ 2025-12-21T23:01:35+00:00 https://fhucare.com/our-publications/maternal-exposure-to-anti-tnf-or-thiopurines-for-ibd-does-not-increase-risk-of-early-life-malignancy-in-children/ 2025-12-21T23:01:36+00:00 https://fhucare.com/our-publications/food-processing-and-risk-of-inflammatory-bowel-disease-a-systematic-review-and-meta-analysis/ 2025-12-21T23:01:37+00:00 https://fhucare.com/our-publications/examining-the-biological-pathways-underlying-clinical-heterogeneity-in-sjogrens-syndrome-proteomic-and-network-analysis/ 2025-12-21T23:01:38+00:00 https://fhucare.com/our-publications/ocular-surface-toxicities-associated-with-modern-anticancer-therapies/ 2025-12-21T23:01:39+00:00 https://fhucare.com/our-publications/comparison-between-primary-sjogrens-disease-patients-with-high-or-low-level-of-dryness/ 2025-12-21T23:01:40+00:00 https://fhucare.com/our-publications/secondary-hypertrophic-osteoarthropathy-revealing-a-metastatic-melanoma/ 2025-12-21T23:01:41+00:00 https://fhucare.com/our-publications/association-between-brutons-tyrosine-kinase-gene-overexpression-and-risk-of-lymphoma-in-primary-sjogrens-syndrome/ 2025-12-21T23:01:42+00:00 https://fhucare.com/our-publications/delivering-adapted-physical-activity-by-videoconference-to-patients-with-fatigue-under-immune-checkpoint-inhibitors-lessons-learned-from-the-pactime-feas-feasibility-study/ 2025-12-21T23:01:43+00:00 https://fhucare.com/our-publications/risk-of-cancer-for-patients-with-rheumatoid-arthritis-versus-general-population-a-national-claims-database-cohort-study/ 2025-12-21T23:01:44+00:00 https://fhucare.com/our-publications/sjogren-syndrome-a-forgotten-or-an-overdiagnosed-entity/ 2025-12-21T23:01:45+00:00 https://fhucare.com/our-publications/immune-checkpoint-inhibitor-rechallenge-in-patients-who-previously-experienced-immune-related-inflammatory-arthritis-a-multicentre-observational-study/ 2025-12-21T23:01:46+00:00 https://fhucare.com/our-publications/immunosuppressant-mycophenolate-mofetil-for-patients-with-steroid-refractory-immune-related-hepatitis-induced-by-checkpoint-inhibitors-in-oncology/ 2025-12-21T23:01:47+00:00 https://fhucare.com/our-publications/serum-and-tissue-biomarkers-associated-with-cress-and-star-response-to-b-cell-targeted-therapy-in-tractiss-trial-of-sjogrens-syndrome/ 2025-12-21T23:01:48+00:00 https://fhucare.com/our-publications/epidemiology-of-sjogren-syndrome/ 2025-12-21T23:01:49+00:00 https://fhucare.com/our-publications/the-perfuse-study-the-experience-of-patients-receiving-adalimumab-biosimilar-sb5/ 2025-12-21T23:01:50+00:00 https://fhucare.com/our-publications/serious-immune-related-upper-gastrointestinal-toxicity-of-immune-checkpoint-inhibitors-a-multicenter-case-series/ 2025-12-21T23:01:51+00:00 https://fhucare.com/our-publications/immune-checkpoints-are-predominantly-co-expressed-by-clonally-expanded-cd4foxp3-intratumoral-t-cells-in-primary-human-cancers/ 2025-12-21T23:01:52+00:00 https://fhucare.com/our-publications/safety-of-vedolizumab-and-ustekinumab-compared-with-anti-tnf-in-pregnant-women-with-inflammatory-bowel-disease/ 2025-12-21T23:01:53+00:00 https://fhucare.com/our-publications/managing-cancer-immunotherapy-toxicities-challenges-and-rechallenges-for-young-internists/ 2025-12-21T23:01:54+00:00 https://fhucare.com/our-publications/identification-of-outcome-domains-in-primary-sjogrens-disease-a-scoping-review-by-the-omeract-sjogren-disease-working-group/ 2025-12-21T23:01:55+00:00 https://fhucare.com/our-publications/obinutuzumab-in-patients-with-sjogrens-disease-immunised-against-rituximab/ 2025-12-21T23:01:56+00:00 https://fhucare.com/our-publications/dietary-index-based-on-the-food-standards-agency-nutrient-profiling-system-and-risk-of-crohns-disease-and-ulcerative-colitis/ 2025-12-21T23:01:57+00:00 https://fhucare.com/our-publications/tofacitinib-for-patients-with-anti-tnf-refractory-ulcerative-proctitis-a-multicentre-cohort-study-from-the-getaid/ 2025-12-21T23:01:58+00:00 https://fhucare.com/our-publications/identification-of-distinct-subgroups-of-sjogrens-disease-by-cluster-analysis-based-on-clinical-and-biological-manifestations-data-from-the-cross-sectional-paris-saclay-and-the-prospective-assess-coh/ 2025-12-21T23:01:59+00:00 https://fhucare.com/our-publications/high-rate-of-progression-to-symptomatic-multiple-myeloma-in-patients-with-smoldering-myeloma-and-isolated-osteoporotic-vertebral-fracture/ 2025-12-21T23:02:00+00:00 https://fhucare.com/our-publications/evolution-of-monoclonal-gammopathy-of-undetermined-significance-in-patients-treated-with-jak-inhibitors-for-rheumatic-diseases-data-from-the-majik-sfr-registry/ 2025-12-21T23:02:01+00:00 https://fhucare.com/our-publications/clonal-cd8-t-cell-expansion-is-associated-with-complete-response-to-elranatamab-in-refractory-multiple-myeloma/ 2025-12-21T23:02:02+00:00 https://fhucare.com/our-publications/reporting-and-analysis-of-immunotherapy-trials-adverse-events-what-is-going-wrong-how-to-do-better/ 2025-12-21T23:02:03+00:00 https://fhucare.com/our-publications/listeria-monocytogenes-associated-spontaneous-bacterial-peritonitis-in-france-a-nationwide-observational-study-of-208-cases/ 2025-12-21T23:02:04+00:00 https://fhucare.com/our-publications/complete-remission-after-a-single-bisphosphonate-infusion-in-isolated-bone-langerhans-cell-histiocytosis-lesion-a-case-report-and-a-narrative-review-of-the-literature/ 2025-12-21T23:02:05+00:00 https://fhucare.com/our-publications/chronic-gastrointestinal-immune-related-adverse-events-in-patients-exposed-to-immune-checkpoint-inhibitors/ 2025-12-21T23:02:06+00:00 https://fhucare.com/our-publications/drug-induced-autoimmune-hemolyticanemias-related-to-immune-checkpoint-inhibitors-therapeutic-management-and-outcome/ 2025-12-21T23:02:07+00:00 https://fhucare.com/our-publications/immune-checkpoint-inhibitor-use-during-pregnancy-and-outcomes-in-pregnant-individuals-and-newborns/ 2025-12-21T23:02:08+00:00 https://fhucare.com/our-publications/society-for-immunotherapy-of-cancer-sitc-recommendations-on-intratumoral-immunotherapy-clinical-trials-iict-from-premalignant-to-metastatic-disease/ 2025-12-21T23:02:09+00:00 https://fhucare.com/our-publications/impact-of-immunosuppressive-agents-on-the-management-of-immune-related-adverse-events-of-immune-checkpoint-blockers/ 2025-12-21T23:02:10+00:00 https://fhucare.com/our-publications/immune-checkpoint-inhibitor-induced-sicca-syndrome/ 2025-12-21T23:02:11+00:00 https://fhucare.com/our-publications/immune-checkpoint-inhibitor-induced-inflammatory-arthritis-current-approaches-to-management/ 2025-12-21T23:02:12+00:00 https://fhucare.com/our-publications/editorial-another-brick-in-the-cdst-wall/ 2025-12-21T23:02:13+00:00 https://fhucare.com/our-publications/toxicity-of-immunotherapy-combinations-with-chemotherapy-across-tumor-indications-current-knowledge-and-practical-recommendations/ 2025-12-21T23:02:14+00:00 https://fhucare.com/our-publications/reactions-and-adverse-events-induced-by-t-cell-engagers-as-anti-cancer-immunotherapies-a-comprehensive-review/ 2025-12-21T23:02:15+00:00 https://fhucare.com/our-publications/drug-induced-autoimmune-hemolytic-anemias-related-to-immune-checkpoint-inhibitors-therapeutic-management-and-outcome/ 2025-12-21T23:02:16+00:00 https://fhucare.com/our-publications/treatment-modalities-of-marginal-zone-lymphoma-and-overall-survival-haematological-response-and-underlying-sjogrens-disease-activity-a-multicentre-retrospective-observational-study/ 2025-12-21T23:02:17+00:00 https://fhucare.com/our-publications/safety-and-efficacy-of-subcutaneous-iscalimab-cfz533-in-two-distinct-populations-of-patients-with-sjogrens-disease-twinss-week-24-results-of-a-randomised-double-blind-placebo-controlled-phase/ 2025-12-21T23:02:18+00:00 https://fhucare.com/our-publications/safety-and-tolerability-of-immune-checkpoint-inhibitors-in-people-with-hiv-infection-and-cancer-insights-from-the-national-prospective-real-world-oncovihac-anrs-co24-cohort-study/ 2025-12-21T23:02:19+00:00 https://fhucare.com/our-publications/cancer-risk-of-janus-kinase-inhibitors-and-biological-disease-modifying-antirheumatic-drugs-among-older-americans-with-rheumatoid-arthritis/ 2025-12-21T23:02:20+00:00 https://fhucare.com/our-publications/car-t-cell-therapy-in-autoimmune-diseases-where-are-we-and-where-are-we-going/ 2025-12-21T23:02:21+00:00 https://fhucare.com/our-publications/car-t-cell-therapy-for-juvenile-onset-autoimmune-diseases-a-promising-future/ 2025-12-21T23:02:22+00:00 https://fhucare.com/our-publications/development-of-salivary-gland-organoids-derived-from-patient-biopsies-a-functional-model-of-sjogrens-disease/ 2025-12-21T23:02:23+00:00 https://fhucare.com/our-publications/gut-microbiota-modulation-through-akkermansia-spp-supplementation-increases-car-t-cell-potency/ 2025-12-21T23:02:24+00:00 https://fhucare.com/our-publications/primary-sjogrens-disease-a-review-of-unmet-need-outcome-measures-therapeutic-advances-and-health-economic-impacts-lessons-from-the-new-clinical-endpoints-in-primary-sjogrens-syndrome-an-interve/ 2025-12-21T23:02:25+00:00 https://fhucare.com/our-publications/expanded-senescent-cd8-t-cells-in-imid-patients-are-associated-with-distinct-inflammatory-cytokines/ 2025-12-21T23:02:26+00:00 https://fhucare.com/our-publications/can-ai-be-used-to-classify-the-focus-score-in-sjogrens-disease/ 2025-12-21T23:02:27+00:00 https://fhucare.com/our-publications/machine-learning-to-classify-the-focus-score-and-sjogrens-disease-using-digitalised-salivary-gland-biopsies-a-retrospective-cohort-study/ 2025-12-21T23:02:28+00:00 https://fhucare.com/our-publications/immune-related-adverse-events-occurring-rapidly-after-a-single-dose-of-immune-checkpoint-blockade/ 2025-12-21T23:02:29+00:00 https://fhucare.com/our-publications/evaluation-of-readministration-of-immune-checkpoint-inhibitors-after-immune-related-adverse-events-in-patients-with-cancer/ 2025-12-24T02:13:58+00:00 https://fhucare.com/our-publications/primary-sjogrens-syndrome/ 2025-12-24T02:14:36+00:00 https://fhucare.com/our-publications/b-cells-in-the-pathogenesis-of-primary-sjogren-syndrome/ 2025-12-24T02:14:51+00:00 https://fhucare.com/our-publications/anticancer-immunotherapy-by-ctla-4-blockade-relies-on-the-gut-microbiota/ 2025-12-24T02:15:06+00:00 https://fhucare.com/our-publications/gut-microbiome-influences-efficacy-of-pd-1-based-immunotherapy-against-epithelial-tumors/ 2025-12-24T02:15:24+00:00 https://fhucare.com/our-publications/baseline-gut-microbiota-predicts-clinical-response-and-colitis-in-metastatic-melanoma-patients-treated-with-ipilimumab/ 2025-12-24T02:17:47+00:00 https://fhucare.com/our-publications/association-between-use-of-thiopurines-or-tumor-necrosis-factor-antagonists-alone-or-in-combination-and-risk-of-lymphoma-in-patients-with-inflammatory-bowel-disease/ 2025-12-24T02:17:53+00:00 https://fhucare.com/our-publications/rheumatoid-arthritis-and-polymyalgia-rheumatica-occurring-after-immune-checkpoint-inhibitor-treatment/ 2025-12-24T02:17:59+00:00 https://fhucare.com/our-publications/management-of-immune-checkpoint-blockade-dysimmune-toxicities-a-collaborative-position-paper/ 2025-12-24T02:18:07+00:00 https://fhucare.com/our-publications/association-of-the-autoimmune-disease-scleroderma-with-an-immunologic-response-to-cancer/ 2025-12-24T02:18:14+00:00 https://fhucare.com/our-publications/high-rate-of-progression-to-symptomatic-multiple-myeloma-in-smoldering-myeloma-with-isolated-osteoporotic-vertebral-fracture/ 2026-02-10T14:26:32+00:00 https://fhucare.com/our-publications/complete-remission-after-a-single-bisphosphonate-infusion-in-isolated-bone-langerhans-cell-histiocytosis/ 2026-02-10T14:26:41+00:00 https://fhucare.com/our-publications/treatment-modalities-of-marginal-zone-lymphoma-and-outcomes-in-sjogrens-disease/ 2026-02-10T14:26:49+00:00 https://fhucare.com/our-publications/evaluation-of-ra-associated-interstitial-lung-disease-in-patients-treated-with-jak-inhibitors-majik-sfr-cohort/ 2026-02-10T14:28:06+00:00 https://fhucare.com/our-publications/car-t-cell-therapy-in-autoimmune-diseases-where-are-we-and-where-are-we-going-2/ 2026-02-10T14:28:13+00:00 https://fhucare.com/our-publications/primary-sjogrens-disease-a-review-of-unmet-need-outcome-measures-therapeutic-advances-and-health-economic-impacts/ 2026-02-10T14:28:22+00:00 https://fhucare.com/our-publications/distinct-pathophysiologic-pathways-support-stratification-of-sjogrens-disease/ 2026-02-10T14:28:28+00:00 https://fhucare.com/our-publications/cancer-risk-of-jak-inhibitors-and-biologics-among-older-americans-with-rheumatoid-arthritis/ 2026-02-10T14:28:35+00:00 https://fhucare.com/our-publications/transcriptomic-stratification-predicts-response-to-rituximab-abatacept-or-hcqleflunomide-in-3-rcts-of-sjogrens-disease/ 2026-02-10T14:28:42+00:00 https://fhucare.com/our-publications/french-recommendations-for-assessing-and-managing-the-risk-of-cancer-before-initiating-targeted-therapies-for-chronic-rheumatic-inflammatory-diseases/ 2026-02-10T14:28:49+00:00 https://fhucare.com/our-publications/molecular-profiling-and-risk-stratification-in-solitary-bone-plasmacytoma/ 2026-02-10T14:28:55+00:00 https://fhucare.com/our-publications/immune-related-adverse-events-occurring-rapidly-after-a-single-dose-of-immune-checkpoint-blockade-2/ 2026-02-10T14:29:01+00:00 https://fhucare.com/our-publications/car-t-cell-mediated-bone-marrow-inflammation-causes-hematotoxicity-and-favors-clonal-hematopoiesis/ 2026-02-10T14:29:08+00:00 https://fhucare.com/our-publications/infectious-complications-in-patients-treated-with-t-cell-engagers-as-cancer-immunotherapies-a-descriptive-study-from-the-reisamic-registry/ 2026-02-13T16:26:21+00:00 https://fhucare.com/our-publications/breaking-the-link-il-6-targeting-to-uncouple-toxicity-and-efficacy-in-patients-treated-with-immune-checkpoint-blockade/ 2026-02-13T16:26:30+00:00 https://fhucare.com/our-publications/immune-checkpoint-inhibitors-associated-vasculitis-a-heterogeneous-condition-with-possible-severe-disease-course/ 2026-02-13T16:26:39+00:00 https://fhucare.com/our-publications/long-term-immune-related-adverse-events/ 2026-02-13T16:26:46+00:00 https://fhucare.com/our-publications/salivary-gland-organoids-and-the-future-of-modeling-autoimmune-epithelitis-in-sjogrens-disease/ 2026-02-13T16:27:04+00:00 https://fhucare.com/our-publications/a-genetic-variant-of-baff-is-associated-with-the-risk-of-lymphoma-in-sjogren-disease/ 2026-02-13T16:27:10+00:00 https://fhucare.com/our-publications/evolution-and-prospects-for-the-definition-of-clinically-useful-endpoints-in-sjogren-disease/ 2026-03-09T09:35:39+00:00 https://fhucare.com/our-publications/the-sjd-map-an-interactive-pathway-tour-into-sjogrens-disease-signalling-mechanisms/ 2026-04-17T12:48:12+00:00